AI-designed personalized mRNA cancer vaccine succeeds in Phase 3; Moderna stock jumps 110%
AI寒武纪 · wechat · 2026-08-20
Moderna and Merck announced that their personalized mRNA melanoma vaccine intismeran (mRNA-4157) combined with KEYTRUDA met both primary endpoints in the Phase 3 INTerpath-001 trial — the first personalized neoantigen therapy ever to succeed in Phase 3. Moderna shares surged over 110% on the news.
The therapy sequences a patient's tumor and healthy DNA, then uses an AI algorithm to select up to 34 neoantigen targets for a bespoke mRNA vaccine that trains the immune system to hunt cancer cells. Prior Phase 2 five-year follow-up showed a 49% reduction in recurrence or death risk and 59% reduction in distant metastasis or death, with 5-year disease-free survival rising from 49.1% to 68.8%. AI also powers Moderna's Maestro system that orchestrates production scheduling and delivery of each patient's batch.
The INTerpath program spans 9 Phase 2/3 trials across melanoma, NSCLC, bladder and renal cancer, with the NSCLC Phase 3 already recruiting. Full data will be presented at an upcoming medical meeting, with regulatory submissions planned.
More from Research
- Dev critiques compiling fast programs into slow neural nets: fun, but not useful — ctjlewis · 2026-10-16
- New paper uses revealed-preference methods to unpack why AI agents cooperate — brwilder · 2026-10-16
- Logit lens on a Beat Saber finetune reveals it reuses language grammar circuits — ctjlewis · 2026-10-16
- 128×128 record stands: how intermediate-work experiments foreshadowed reasoning models — ctjlewis · 2026-10-16
- TeamFusion: preference-based AI proxies debate to preserve minority views in team decisions — burkov · 2026-10-16
- MIT's C-GMT gives humanoid robots whole-body compliance without sacrificing motion tracking — MIT_CSAIL · 2026-10-16